Company: Onyx Pharmaceuticals (ONXX)
Drug/indication: Carfilzomib for multiple myeloma
Estimated timing: Third quarterRecent stock performance: Down 28% and near its 52-week low. Onyx acquired the next-generation proteasome inhibitor carfilzomib when the company bought the privately held drug developer Proteolix in October 2009. This "pivotal" phase IIb study enrolled 269 patients with multiple myeloma that continued to grow despite two or three prior therapies. If carfilzomib can shrink tumors in a significant portion of these patients, Onyx intends to seek accelerated approval with the FDA.